3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Small Cell Lung Carcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Urinary Bladder Neoplasms
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Non Small Cell Lung Cancer NSCLC
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
3
Paclitaxel
3
Carboplatin
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
sacituzumab govitecan
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
olaparib
1
lenvatinib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
durvalumab
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Trastuzumab
1
Taxes
1
Sunitinib
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Endometrial Neoplasms
×
durvalumab
×
Clear all
NCT04269200
2026-06-01
DUO-E
AstraZeneca
Phase 3
Active not recruiting
805 enrolled
18 charts
1 FDA